Overview

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the clinical efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.